Eiger BioPharmaceuticals, Inc. (EIGRQ)
USD 8.5
(6.25%)
USD 8.5
(6.25%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 41.2 Million USD | 2.5% |
| 2022 | 40.19 Million USD | 23.54% |
| 2021 | 32.53 Million USD | 0.08% |
| 2020 | 32.51 Million USD | 0.84% |
| 2019 | 32.24 Million USD | 25.85% |
| 2018 | 25.62 Million USD | 69.75% |
| 2017 | 15.09 Million USD | 2.49% |
| 2016 | 14.72 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q1 | 40.42 Million USD | 0.56% |
| 2023 Q2 | 40.67 Million USD | 0.61% |
| 2023 FY | 41.2 Million USD | 2.5% |
| 2023 Q3 | 40.93 Million USD | 0.66% |
| 2023 Q4 | 41.2 Million USD | 0.64% |
| 2022 Q3 | 39.59 Million USD | 0.61% |
| 2022 Q1 | 32.58 Million USD | 0.15% |
| 2022 FY | 40.19 Million USD | 23.54% |
| 2022 Q4 | 40.19 Million USD | 1.53% |
| 2022 Q2 | 39.35 Million USD | 20.76% |
| 2021 Q2 | 32.42 Million USD | 0.0% |
| 2021 FY | 32.53 Million USD | 0.08% |
| 2021 Q4 | 32.53 Million USD | 0.18% |
| 2021 Q3 | 32.47 Million USD | 0.16% |
| 2020 FY | 32.51 Million USD | 0.84% |
| 2019 FY | 32.24 Million USD | 25.85% |
| 2018 FY | 25.62 Million USD | 69.75% |
| 2017 FY | 15.09 Million USD | 2.49% |
| 2016 FY | 14.72 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -899.598% |
| SQZ Biotechnologies Company | 27.47 Million USD | -49.987% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 5.003% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | -38.418% |
| Mesoblast Limited | 118.7 Million USD | 65.288% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -4245.066% |
| Genus plc | 233.1 Million USD | 82.324% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -1306.06% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -2966.649% |
| Marizyme, Inc. | 18.71 Million USD | -120.131% |
| ContraFect Corporation | 2.88 Million USD | -1330.163% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -5393.733% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -30311.036% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -2748.818% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -1671.444% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -628.18% |
| MultiCell Technologies, Inc. | 202.58 USD | -20339025.284% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 28.329% |
| EV Biologics, Inc. | 1.49 Million USD | -2656.513% |
| Q BioMed Inc. | 4.1 Million USD | -902.511% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | -24.477% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -6439.359% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -3254.307% |
| Biomind Labs Inc. | 735.54 Thousand USD | -5501.72% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 75.981% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -217.019% |
| Skye Bioscience, Inc. | 4.61 Million USD | -792.755% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -4539.643% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -29015.024% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -601.795% |
| IMV Inc. | 28.88 Million USD | -42.65% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -160104.518% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -1724.449% |
| GB Sciences, Inc. | 1.75 Million USD | -2242.002% |
| Alpha Cognition Inc. | 1.22 Million USD | -3276.266% |
| HST Global, Inc. | 98.31 Thousand USD | -41807.464% |
| CSL Limited | 12.18 Billion USD | 99.662% |
| Halberd Corporation | 150 Thousand USD | -27368.667% |
| Enzolytics Inc. | 996.33 Thousand USD | -4035.444% |
| Resverlogix Corp. | 6.49 Million USD | -534.771% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -8528.901% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -16020.614% |
| argenx SE | 20 Million USD | -106.015% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 9.563% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -1421.134% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -402863.325% |
| Genscript Biotech Corporation | 417.73 Million USD | 90.137% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -20438.242% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -1618.421% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -17869.742% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 39.087% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -1261.547% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -11354.505% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | -102.691% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -27617.384% |
| BioStem Technologies, Inc. | 4.71 Million USD | -774.535% |
| ONE Bio Corp. | 19.71 Million USD | -108.993% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -16369.21% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -16466.018% |
| Agentix Corp. | 50 Thousand USD | -82306.0% |
| LadRx Corporation | 33.6 Thousand USD | -122506.082% |
| Cell Source, Inc. | 9.25 Million USD | -345.237% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -5348.662% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -5348.662% |
| NovAccess Global Inc. | 2.19 Million USD | -1772.966% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -482.555% |
| Itoco Inc. | 228.37 Thousand USD | -17941.659% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -19429.802% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -726.871% |
| Kadimastem Ltd | 891.22 Thousand USD | -4523.182% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -10153.354% |
| CytoDyn Inc. | 30.07 Million USD | -36.996% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -8408.024% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -11610.488% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -426.895% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -33535.102% |
| Rebus Holdings, Inc. | 310 Thousand USD | -13191.29% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -770.128% |
| International Stem Cell Corporation | 4.17 Million USD | -886.19% |
| Bioxytran, Inc. | 1.92 Million USD | -2040.416% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -65916.695% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -1789.266% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -395.467% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -379.942% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -2548.895% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -15274.254% |
| Neutra Corp. | 54.15 Thousand USD | -75982.059% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -2151.53% |
| PureTech Health plc | 25.51 Million USD | -61.504% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -3265.637% |
| IXICO plc | 472.02 Thousand USD | -8629.024% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -165.809% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 33.824% |
| CSL Limited | 12.18 Billion USD | 99.662% |
| Cellectis S.A. | 92.77 Million USD | 55.589% |